Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Interferon α2b Vaginal Effervescent Tablets for Cervical High-Risk HPV Infection
ChiCTR2200060086Phase 4Completed
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Oct 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of interferon alfa-2b in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Cervical samples showed no high-risk HPV. Started Oct 2018; status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on ChiCTR2200060086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060086.